I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Nilofer Saba Azad, M.D.
Associate Professor of Oncology
Languages: English, Hindi, Urdu
Expertise: Anal Cancer, Bile Duct Cancer, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Clinical Trials, Colon Cancer, Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, Hepatocellular Cancer, Liver Cancer, Medical Oncology, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Small Intestine Cancer, Stomach Cancer ...read more
Research Interests: GI Cancers: Colorectal, pancreatobiliary
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Sibley Memorial Hospital
Appointment Phone: 202-660-6500
5255 Loughboro Road NW
Washington, DC 20016 map
Dr. Nilofer S. Azad is an associate professor of oncology at Johns Hopkins University School of Medicine. Dr. Azad is board certified in medical oncology and directs the Phase I Clinical Trials Program for the Johns Hopkins Kimmel Cancer Center.
Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She complete a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland and was named chief fellow during her time there.
Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a particular concentration in colorectal and pancreatobiliary cancer. Her research efforts are dedicated to developing new drugs for patients with advanced cancer, with a focus on using epigenetic agents in combination with chemotherapy and immunotherapy to improve survival for patients. She also has led multiple clinical trials of molecularly targeted agents for advanced cancer patients.
- Associate Professor of Oncology
- MD, Baylor College of Medicine (2001)
- Baylor College of Medicine / Internal Medicine (2004)
- National Cancer Institute- NIH / Oncology and Hematology (2008)
- American Board of Internal Medicine / Medical Oncology (2007)
Research & Publications
Clinical Trial Keywordscolorectal cancer, pancreatic cancer, cholangiocarcinoma, bile duct cancer
Selected PublicationsView all on Pubmed
Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, Joffe C,
Petito E, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Siu
LL, Azad NS. A Phase I study of veliparib (ABT-888) in combination with low-dose
fractionated whole abdominal radiation therapy in patients with advanced solid
malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2015 Jan
1;21(1):68-76. doi: 10.1158/1078-0432.CCR-14-1552. Epub 2014 Oct 29. PubMed PMID:
25355929; PubMed Central PMCID: PMC428649
Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS. CHFR
silencing or microsatellite instability is associated with increased antitumor
activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer. 2014 Feb
1;134(3):596-605. doi: 10.1002/ijc.28390. Epub 2013 Aug 24. PubMed PMID:
23873170; PubMed Central PMCID: PMC3830586.5
Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013 May;10(5):256-66. doi: 10.1038/nrclinonc.2013.42. Epub 2013 Apr 2. Review. PubMed PMID: 23546521;
PubMed Central PMCID: PMC3730253
Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab,
rinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr;31(2):345-54. doi: 10.1007/s10637-012-9820-z. Epub 2012 May 22. PubMed PMID: 22615057; PubMed Central PMCID: PMC3674958
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363. Figg, William D [added]. PubMed PMID: 18669456.